

**Fig 1 The structure of the Vaccibody.**






Fig 2 Principle.




**Fig 3 Flow cytometry of splenocytes**



**Fig 4 The NIP-specific control Vaccibodies exhibits binding to the hapten NIP.**

5/25



**Fig 5 The Vaccibodies exhibit binding to DNP, hence the antigenic scFv is correctly folded.**

6/25





Fig 6 APC pulsed with titrated amounts of MHC class II specific Vaccibodies


7/25




**Fig 7 The MHC class II-specific Vaccibodies induce a strong anti-Id Ab response in the absence of adjuvants.**

8/25

**A Short hinge**




**B long hinge**



**Fig 8 Construction of the two hinge-Cy3 variants of hIgG3 origin by PCR.**




9/25



**Fig 9 Construction of the hinge-C $\gamma$ 3 segments derived from mIgG2b.**

10/25



**Fig 10 Construction of the scFv derived from the myeloma protein M315.**

11/25






Fig 11 Joining of the hinge-Cy3 segments and the M315 scFv by PCR soeing.

12/25




**Fig 12 Subcloning of the hinge-C $\gamma$ 3-M315 scFv into pUC19.**

13/25




**Fig 13 Removal of two inconvenient BamHI restriction enzyme sites by QuickChange PCR.**

14/25




**Fig 14 Introduction of stop codon, a SfiI and a BamHI restriction enzyme site downstream of the coding region by QuickChange PCR.**

15/25



**Fig 15 Subcloning into the C cassette of the expression vector pLNOH<sub>2</sub> on HindII-BamHI**

16/25



**Fig 16 Cloning of the V regions specific for NIP and MHCII and assembling into a scFv format by PCR soeing.**



17/25






Fig 17 Subcloning into the expression vector pLNOH<sub>2</sub> on BsmI/MunI and BsiWI

18/25




**Fig 18 The final Vaccibody construct.**

19/25



**Fig 19 The Vaccibody gene construct**

20/25



**Fig 20 Vaccibodies are secreted as functional molecules.**

**21/25**

22/25






Fig 22 Tumor avoidance.

23/25




**Fig 23 Induction of protective immunity against the MOPC315.4 plasmacytoma.**





25/25



**Fig 25 Chemokine Vaccibodies are secreted as functional molecules.**